Table 4 MICA-LDA performance on six mass spectral data sets
From: A high performance profile-biomarker diagnosis for mass spectral profiles
Cross validation | Ave. classification rate ± std (%) | Ave. sensitivity ± std (%) | Ave. specificity ± std (%) |
|---|---|---|---|
50%HOCV | |||
Colorectal | 96.21±02.07 | 96.20±03.70 | 96.29±02.53 |
HCC | 98.19±01.67 | 100.0±00.00 | 96.50±03.21 |
Ovarian-qaqc | 90.62±02.73 | 91.93±04.67 | 89.58±04.05 |
Prostate | 93.03±03.05 | 96.15±03.24 | 89.42±05.24 |
Cirrhotic | 98.93±01.37 | 97.52±03.05 | 99.97±00.28 |
Three-class | 96.84±01.32 | 98.69±01.49 | 96.21±02.10 |
10-fold CV | |||
Colorectal | 96.26 ± 06.77 | 95.00 ± 15.81 | 96.90 ± 06.55 |
HCC | 97.38 ± 03.39 | 100.0 ± 00.00 | 95.00 ± 06.45 |
Ovarian-qaqc | 88.46 ± 07.16 | 91.78 ± 13.41 | 86.03 ± 06.54 |
Prostate | 90.87 ± 07.86 | 92.86 ± 10.10 | 88.57 ± 13.65 |
Cirrhotic | 99.17 ± 02.64 | 98.00 ± 06.32 | 100.0 ± 00.00 |
Three-class | 97.33 ± 03.44 | 96.25 ± 06.04 | 98.57 ± 04.52 |